Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
25 June 2025
Psychiatry Interest Forum (PIF) Program at Congress 2025
Forty-one (41) PIF medical students and junior doctors were fully supported to attend the Congress i...
24 June 2025
CPD Evaluation survey 2025
A survey on the RANZCP CPD Program is open until 18 July 2025. Any information you provide is anonym...
20 June 2025
Australian Launch of “Achieving gender justice for global health equity: the Lancet Commission on gender and global health”
The RANZCP was proudly represented today by Dr Michelle Atchison at the Australian launch of "Achiev...